Hangzhou Alltest Biotech Co. Ltd. A
Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; flu… Read more
Hangzhou Alltest Biotech Co. Ltd. A (688606) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.014x
Based on the latest financial reports, Hangzhou Alltest Biotech Co. Ltd. A (688606) has a cash flow conversion efficiency ratio of 0.014x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥55.21 Million) by net assets (CN¥3.90 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hangzhou Alltest Biotech Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Hangzhou Alltest Biotech Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hangzhou Alltest Biotech Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hangzhou Alltest Biotech Co. Ltd. A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Excelsior Medical Co Ltd
TW:4104
|
-0.022x |
|
Gunkul Engineering Public Company Limited
BK:GUNKUL-R
|
0.039x |
|
NWTN Inc. Class B Ordinary Shares
NASDAQ:NWTN
|
0.062x |
|
Insight Acquisition Corp. Units
NASDAQ:INAQU
|
0.091x |
|
Shanghai Prisemi Electronics Co Ltd
SHG:688230
|
0.012x |
|
Actron Technology
TWO:8255
|
0.011x |
|
Northpointe Bancshares, Inc.
NYSE:NPB
|
0.159x |
|
Bumi Armada Bhd
KLSE:5210
|
0.063x |
Annual Cash Flow Conversion Efficiency for Hangzhou Alltest Biotech Co. Ltd. A (2016–2024)
The table below shows the annual cash flow conversion efficiency of Hangzhou Alltest Biotech Co. Ltd. A from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.88 Billion | CN¥329.52 Million | 0.085x | +1212.89% |
| 2023-12-31 | CN¥3.83 Billion | CN¥24.76 Million | 0.006x | -98.02% |
| 2022-12-31 | CN¥4.17 Billion | CN¥1.36 Billion | 0.326x | +15.60% |
| 2021-12-31 | CN¥3.27 Billion | CN¥923.87 Million | 0.282x | -55.92% |
| 2020-12-31 | CN¥972.66 Million | CN¥622.72 Million | 0.640x | +105.08% |
| 2019-12-31 | CN¥293.20 Million | CN¥91.53 Million | 0.312x | +261.00% |
| 2018-12-31 | CN¥215.10 Million | CN¥18.60 Million | 0.086x | -40.04% |
| 2017-12-31 | CN¥138.61 Million | CN¥19.99 Million | 0.144x | -41.34% |
| 2016-12-31 | CN¥27.32 Million | CN¥6.72 Million | 0.246x | -- |